Lidakol n-docosanol data

At the International Conference on Antiviral Research in Charleston, S.C., LDAKA (La Jolla) announced findings in 63 patients with recurring cold sores.

Of 98 episodes analyzed (48 treated, 50 placebo), 20 were treated before blisters formed. The agent reduced mean healing times in the early treatment group by 3.3 days (p = 0.05). It also aborted blister formation in 9 of 13 patients, compared to placebo (2 of 7 patients). ...